Feb 25, 2011 by Brian Orelli, PhDWhen the Companies Know, Investors Should, TooWhy don't more companies preannounce FDA rejections?
Feb 24, 2011 by Brian Orelli, PhDIs This the Biggest Threat to Drug Investors?Reimportation is all bark, no bite.
Feb 24, 2011 by Brian Orelli, PhDAbbott: 1, Johnson & Johnson: 0 -- For NowIn a patent fight, the score could change at any moment.
Feb 24, 2011 by Brian Orelli, PhDYouth in Revolt Against POZENPOZEN fails to get a pediatric extension.
Feb 24, 2011 by Brian Orelli, PhDProfit From Personalized MedicinePfizer's drug works well, but consider these companies instead.
Feb 23, 2011 by Brian Orelli, PhDGilead Gears Up to Fight CancerGilead has been infected by the diversification bug.
Feb 23, 2011 by Brian Orelli, PhDGreat Science, Great Drugs, Not-So-Great ValuationInvestors bid up Vertex.
Feb 22, 2011 by Brian Orelli, PhDA Billion-Dollar Market to Open "Very Soon"Biosimilar drugs are finally coming to the U.S.
Feb 22, 2011 by Brian Orelli, PhDBiogen and Elan's Growing ProblemMore cases of potentially lethal PML.
Feb 18, 2011 by Brian Orelli, PhDThe FDA Has the Final Say (and the One After That)Johnson & Johnson appeals an FDA decision -- don't hold your breath.
Feb 17, 2011 by Brian Orelli, PhDWhat Sanofi-Genzyme Means for the Rest of BiotechThis is no time to celebrate.
Feb 16, 2011 by Brian Orelli, PhDThe Most Important Thing Affecting MerckThe value of its Schering-Plough acquisition hangs on it.
Feb 15, 2011 by Brian Orelli, PhDObama Hates Your DrugmakerThe president's proposal in favor of earlier generics would mean lower profits for some companies.
Feb 11, 2011 by Brian Orelli, PhDBiotech Optimists Throw In the TowelAs the chance of survival improves, the stock falls. Wait, what?
